Healthcare Services company Vimta Labs announced Q2FY24 & H1FY24 results: Total Income for Q2FY24 was at Rs 754 million a de-growth of 6.4% YoY EBITDA for Q2FY24 was Rs 179 million a decline of 31.4% YoY; EBITDA margin was at 23.8% Total Income for H1FY24 was at Rs 1,595 million a de-growth of 0.7% YoY EBITDA for H1FY24 was Rs 432 million a decline of 15.3% YoY; EBITDA margins at 27.1% Cash and Cash equivalents at Rs 262 million as of September 30, 2023 Cash flow From Operations at Rs 268 million for H1FY24; H1FY24 Capex at Rs 421 million Debt to Equity ratio 0.07 Commenting on results, Harita Vasireddi, Managing Director, Vimta Labs, said, “The downtrend in our income has primarily stemmed from the Pharma and Food business, which saw decreased demand and lower volumes respectively. Conversely, our E&E; business continues to perform well, with Environment and Diagnostics remained stable. Given the headwinds from the broader economic uncertainties, we acknowledge the external challenges. However, our ongoing dialogues with clients along with the stability provided by our long-term contracts and revenue visibility for the H2FY24 keeps me optimistic of delivering growth in FY24.” Result PDF